Attached files
| file | filename |
|---|---|
| EX-32.2 - EX-32.2 - Cardiff Oncology, Inc. | crdf-063020exhibit322.htm |
| EX-31.2 - EX-31.2 - Cardiff Oncology, Inc. | crdf-063020exhibit312.htm |
| EX-31.1 - EX-31.1 - Cardiff Oncology, Inc. | crdf-063020exhibit311.htm |
| 10-Q - 10-Q - Cardiff Oncology, Inc. | crdf-20200630.htm |
Exhibit 32.1
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER
PURSUANT TO 18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Quarterly Report of Cardiff Oncology, Inc. (the “Company”) on Form 10-Q for the three months ended June 30, 2020 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Mark Erlander, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
| August 11, 2020 | /s/ Mark Erlander | ||||
| Mark Erlander | |||||
| Chief Executive Officer | |||||